Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

Company Reiterates 2008 Earnings Guidance and Introduces Q1 2008 Guidance

FRAZER, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2007 sales of $1.727 billion, compared to sales of $1.720 billion for 2006, exceeding the company's previously issued guidance. Basic loss per common share for the full year 2007 was $2.88. Excluding the previously announced settlement reserve, amortization expense and certain other items, basic adjusted income per common share for the full year was $4.64, which compares to $5.22 for 2006 and exceeds the high end of the company's earnings guidance range of $4.45 to $4.55.

2007 central nervous system (CNS) franchise sales increased 16 percent to $909.4 million compared to 2006 and the pain franchise reported strong sales of $512.6 million, a decrease of only 22 percent despite a full year of generic competition to ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. Sales of other products increased 15 percent to $305.3 million.

"We delivered strong performance across all aspects of our business in 2007. We launched AMRIX, filed three NDAs, introduced three new Phase 1 programs, and delivered greater sales and earnings than expected," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "We believe that 2008 will mark the beginning of a new phase of growth for the company with a full year of AMRIX sales, the potential for approval of TREANDA and expanded indications for FENTORA, and continued progress on the clinical development plan for NUVIGIL. In fact, the NUVIGIL program is already off to a great start with promising results from our first Phase 2 study in the treatment of schizophrenia."

The company is reiterating its guidance for 2008 total sales of $1.80 - $1.85 billion, adjusted net income of $344 - $351 million and its basic adjusted income per common share guidance of $5.10 - $5.20.

Cephalon is introducing first quarter 2008 sales guidance of $435 - $445 mil
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... BASKING RIDGE, N.J. , Oct. 30, 2014 /PRNewswire/ ... announced that it will hold a conference call and ... 8:30 a.m. EST to discuss its third quarter 2014 ... access the conference call by dialing (888) 347-1165 for ... conference call will be webcast live under the investor ...
(Date:10/27/2014)... 27, 2014 The Italian ... exhibit and sell its artificial "lower limb", after ... patent.      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ... fighting, the definitive judgement has arrived: Roadrunnerfoot, the ... and accessible hi-tech prostheses with composite materials, has ...
Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... Spherix Incorporated (NASDAQ: SPEX ) – ... syndrome and atherosclerosis, and provider of technical and regulatory ... today announced that it has entered into definitive agreements ... stock and warrants to purchase shares of its common ...
... +49(0)69-2222-34066 France: +33(0)1-70-48-01-63 U.K.: +44(0)20-7660-0009 ... is 5634610; to view the webcast, log onto: ... March 13, 2012 - Annual press conference in Goettingen, Germany ... Germany April 24, 2012 - Publication of first-quarter ...
... A relatively fast, easy and inexpensive technique for ... self-assemble into one-, two- and even three-dimensional macroscopic ... researchers with the U.S. Department of Energy (DOE),s ... should enable more effective use of nanorods in ...
Cached Biology Technology:Spherix Announces Registered Direct Offering of $1.15 Million 2Spherix Announces Registered Direct Offering of $1.15 Million 3Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30% 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 3Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 4
(Date:10/31/2014)... In the war against Ebola one important hurdle has ... Researchers at the University of North Carolina at Chapel ... of mice that can be infected with Ebola and ... work, published in the current issue of Science ... and vaccines, which are desperately needed to curb the ...
(Date:10/31/2014)...  HITLAB SM , a healthcare innovation and ... HITLAB Innovators Summit SM on December 1, ... partner with the Clinton Foundation,s Health Matters Initiative, ... Business School Alumni Club of New ... Operations Research, bringing together leaders in healthcare and ...
(Date:10/30/2014)... in German . ... fellow humans to behave socially? This is one of ... theory. Previous studies assumed that it is almost impossible ... the Max Planck Institute for Evolutionary Biology have now ... on the cooperative behaviour of others. However, the possibilities ...
Breaking Biology News(10 mins):Improved mouse model will accelerate research on potential Ebola vaccines, treatments 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4
... This press release is available in German . ... pathogens and rogue cells in the body and put them out ... migrate from there into the thymus. Here, they mature and differentiate ... Institute of Immunobiology and Epigenetics in Freiburg have now succeeded for ...
... Deepwater Horizon oil spill in the Gulf of Mexico in April ... fisheries. A new study published in the Canadian Journal of ... 7 years this oil spill could have a $US8.7 billion impact ... in revenue, profit, and wages, and close to 22 000 jobs ...
... The understanding of diseases such as Parkinson,s and Alzheimer,s ... technology at which will enable cell analysis using automated ... School of Information Communication Technology and the Eskitis Institute ... the automated identification, separation and analysis of cells as ...
Cached Biology News:Live from the thymus: T-cells on the move 2Live from the thymus: T-cells on the move 3
... DNA Polymerase I Large (Klenow) Fragment, Exonuclease ... lacks both the 5´→3´ and the 3´→5´ ... DNA Polymerase I (1,2). It is used ... strand displacement amplification (5). Klenow Fragment, Exonuclease ...
SMVT (N-14)...
...
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is a ... effective in inhibiting retroviral activity. Immunogen: ... Specificity: The specificity of the ... of the moles of ddC to moles of ...
Biology Products: